Anti-B7-H3 antibody-drug conjugate reduced the risk of death by 54% versus topotecan and improved progression-free survival and response rates SEOUL, Republic of Korea, Sept. 13, 2026 /PRNewswire/ -- The phase III TAISHAN-302 trial found that tambotatug pelitecan (Tam-Peli, YL201), a...